Tevogen (TVGN) Change in Cash (2022 - 2026)
Tevogen Bio Holdings' (TVGN) quarterly Change in Cash came in at $139933.0 in Q1 2026, down 79.78% YoY from $691937.0 in Q1 2025, and up 128.87% on a QoQ basis from -$484722.0 in Q4 2025.
Tevogen (TVGN) Change in Cash (2022 - 2026) Analysis & Trends
Tevogen Bio Holdings (TVGN) has 5 years of Change in Cash data on file, last reported at $139933.0 in Q1 2026.
- Quarterly Change in Cash fell 79.78% year-over-year to $139933.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.3 million (down 295.22% YoY) and the FY2025 annual result came in at -$730623.0, down 416.84% from the prior year.
- Change in Cash grew to $139933.0 in Q1 2026, from -$484722.0 in the prior quarter.
- In the past five years, Change in Cash ranged from a high of $1.2 million in Q3 2024 to a low of -$2.2 million in Q2 2023.
- A 5-year average of -$294550.3 and a median of -$45901.0 in 2022 frame the typical range for Change in Cash.
- The widest YoY moves for Change in Cash: up 267.97% in 2023, down 11112.91% in 2023.
- Tracing TVGN's Change in Cash over 5 years: stood at -$13861.0 in 2022, then tumbled by 11112.91% to -$1.6 million in 2023, then soared by 32.59% to -$1.0 million in 2024, then soared by 53.73% to -$484722.0 in 2025, then surged by 128.87% to $139933.0 in 2026.
- The last three Change in Cash figures came in at $139933.0 (Q1 2026), -$484722.0 (Q4 2025), and $351865.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Tevogen | 25.62 Mn | 25.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 139,933.00 |
| Dec 31, 2025 | -484,722.00 |
| Sep 30, 2025 | 351,865.00 |
| Jun 30, 2025 | -1.29 Mn |
| Mar 31, 2025 | 691,937.00 |
| Dec 31, 2024 | -1.05 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | -182,510.00 |
| Mar 31, 2024 | 265,503.00 |
| Dec 31, 2023 | -1.55 Mn |
| Sep 30, 2023 | -849,992.00 |
| Jun 30, 2023 | -2.22 Mn |
| Mar 31, 2023 | 189,865.00 |
| Dec 31, 2022 | -13,861.00 |
| Sep 30, 2022 | -42,598.00 |
| Jun 30, 2022 | -45,901.00 |
| Mar 31, 2022 | -113,035.00 |